Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of combining bendamustine with ofatumumab as first-line therapy for indolent B-cell non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Cephalon | Conditions: Non-Hodgkin's Lymphoma (NHL) | Phase 2 | Status: COMPLETED | Results posted: 2012-08-28